Lipid Metabolism Practice Questions

Q: Low-density lipoproteins (LDL) represents a final stage in the catabolism of VLDL. Which of the following receptors are present in the liver for uptake of LDL?

Apolipoprotein E and Apolipoprotein B100. **Explanation:** The uptake of Low-Density Lipoprotein (LDL) by the liver is mediated by the **LDL Receptor (LDLR)**, also known as the **Apo B100/E receptor**. This receptor is highly specific and recognizes two primary ligands: **Apolipoprotein B100** (the structural protein of VLDL, IDL, and LDL) and **Apolipoprotein E** (found on VLDL, IDL, and Chylomicron remnants). While LDL contains only Apo B100, the receptor itself is structurally designed to bind both proteins, facilitating the clearance of both LDL and IDL (which contains both B100 and E) from the circulation. **Analysis of Options:** * **Option C (Correct):** The LDL receptor is dual-specific. It binds Apo B100 on LDL particles and Apo E on Remnant particles (IDL). * **Option A:** Apo E is the primary ligand for the **LRP (LDL Receptor-related Protein)** and is used for chylomicron remnant uptake, but it is only one half of the LDLR's binding capability. * **Option B:** Apo A is associated with HDL (High-Density Lipoprotein) and is involved in reverse cholesterol transport via the ABCA1 transporter and SR-B1 receptor, not the LDL receptor. * **Option D:** While LDL particles only carry Apo B100, the hepatic receptor that clears them is physiologically characterized as the Apo B100/E receptor. **High-Yield Clinical Pearls for NEET-PG:** 1. **Familial Hypercholesterolemia (Type IIa):** Caused by a genetic defect or absence of the LDL (B100/E) receptor, leading to severely elevated serum LDL and premature atherosclerosis. 2. **PCSK9 Inhibitors:** These drugs prevent the degradation of LDL receptors, increasing their recycling to the hepatocyte surface to lower blood cholesterol. 3. **Wolman Disease:** A lysosomal storage disorder where a deficiency in acid lipase prevents the breakdown of cholesteryl esters after LDL is internalized.

Q: The reaction Acetoacetyl CoA + succinate → succinyl CoA + acetoacetate occurs in all of the following tissues except?

Liver. **Explanation:** The question tests the concept of **Ketolysis** (the utilization of ketone bodies). The reaction described is the activation of acetoacetate into acetoacetyl CoA, which is the rate-limiting step of ketone body utilization. **1. Why Liver is the Correct Answer:** The enzyme responsible for this reaction is **Thiophorase** (also known as Succinyl CoA-Acetoacetate CoA Transferase). While the liver is the primary site for **Ketogenesis** (production of ketone bodies), it lacks the enzyme Thiophorase. This is a crucial physiological adaptation that prevents the liver from consuming the ketone bodies it produces, ensuring they are exported to peripheral tissues for energy during fasting or starvation. **2. Why Other Options are Incorrect:** * **Brain (A):** During prolonged starvation, the brain adapts to use ketone bodies as its primary energy source. It contains high levels of Thiophorase. * **Striated/Skeletal Muscle (B) & Cardiac Muscle (D):** These are extrahepatic tissues that readily utilize ketone bodies for energy, especially when glucose availability is low. They possess the necessary Thiophorase enzyme to convert acetoacetate back into acetyl-CoA for the TCA cycle. **Clinical Pearls & High-Yield Facts:** * **Rate-limiting enzyme of Ketogenesis:** HMG-CoA Synthase (Mitochondrial). * **Rate-limiting enzyme of Ketolysis:** Thiophorase (absent in Liver). * **Ketone Bodies:** Include Acetone (non-metabolizable, exhaled), Acetoacetate, and β-Hydroxybutyrate. * **Organ preference:** The heart actually prefers fatty acids and ketone bodies over glucose under normal physiological conditions.

Q: Which of the following is NOT a phospholipid?

Cerebroside. ### Explanation The classification of lipids is based on their chemical composition. **Phospholipids** must contain a phosphate group as part of their structure, whereas **Glycolipids** contain a carbohydrate moiety instead of phosphate. **Why Cerebroside is the correct answer:** Cerebrosides are **Glycosphingolipids**. They consist of a ceramide backbone (sphingosine + fatty acid) attached to a single sugar unit (usually glucose or galactose). Because they lack a phosphate group, they are classified as glycolipids, not phospholipids. **Analysis of Incorrect Options:** * **Sphingomyelin:** This is the only **phospholipid** that does not have a glycerol backbone; it uses sphingosine instead. However, because it contains a phosphate group (phosphorylcholine), it is classified as a sphingophospholipid. * **Cephalin (Phosphatidylethanolamine):** A major glycerophospholipid found in cell membranes, particularly in nervous tissue. It contains glycerol, fatty acids, phosphate, and ethanolamine. * **Cardiolipin (Diphosphatidylglycerol):** An important glycerophospholipid found exclusively in the **inner mitochondrial membrane**. It is essential for the optimal function of the electron transport chain. **High-Yield Clinical Pearls for NEET-PG:** 1. **Cardiolipin:** Decreased levels are associated with **Barth Syndrome**, and it is the antigen used in the **VDRL test** for Syphilis. 2. **Sphingomyelin:** Accumulates in **Niemann-Pick Disease** due to a deficiency of the enzyme sphingomyelinase. 3. **Lecithin (Phosphatidylcholine):** The most abundant phospholipid in the cell membrane; its ratio to sphingomyelin (L:S ratio) in amniotic fluid is a marker for **fetal lung maturity**. 4. **Phosphatidylinositol:** Acts as a precursor for second messengers like $IP_3$ and $DAG$.

Q: What is the function of LCAT?

Converts cholesterol to cholesterol ester. **Explanation:** **LCAT (Lecithin-Cholesterol Acyltransferase)** is a plasma enzyme synthesized by the liver and associated primarily with **High-Density Lipoprotein (HDL)**. 1. **Why Option B is Correct:** LCAT catalyzes the transfer of a fatty acid from the C2 position of lecithin (phosphatidylcholine) to the free hydroxyl group of cholesterol. This reaction produces **cholesterol esters** and lysolecithin. Because cholesterol esters are more hydrophobic than free cholesterol, they move from the surface of the HDL particle into its core. This process is the fundamental step in **Reverse Cholesterol Transport**, allowing HDL to "trap" cholesterol from peripheral tissues and transport it back to the liver. 2. **Why Other Options are Incorrect:** * **Option A:** Cholesterol synthesis occurs intracellularly (primarily in the liver and intestines) via the HMG-CoA reductase pathway, not by LCAT. * **Option C:** Chylomicron formation occurs in the intestinal mucosal cells and requires Apo B-48 and MTP (Microsomal Triglyceride Transfer Protein), not LCAT. **High-Yield Clinical Pearls for NEET-PG:** * **Activator:** LCAT is specifically activated by **Apo A-I** (the major apoprotein of HDL). * **Intracellular Counterpart:** While LCAT esterifies cholesterol in the *plasma*, the enzyme **ACAT** (Acyl-CoA:cholesterol acyltransferase) performs this function *inside cells*. * **Clinical Correlation:** Deficiency of LCAT leads to **Fish-eye disease** or Familial LCAT deficiency, characterized by corneal opacities, hemolytic anemia, and renal failure due to the accumulation of free cholesterol in tissues.

Q: Which of the following contains an aromatic ring?

Estradiol. **Explanation:** The core concept tested here is the structural difference between various steroid hormones. All steroid hormones are derived from cholesterol and share the **cyclopentanoperhydrophenanthrene (sterane)** nucleus, but their saturation and functional groups vary significantly. **Why Estradiol is Correct:** Estradiol (E2) is an estrogen. The defining structural feature of estrogens (C18 steroids) is the **aromatization of the 'A' ring**. During steroidogenesis, the enzyme **aromatase** (CYP19A1) converts androgens into estrogens by removing the C19 methyl group and creating three alternating double bonds in the A-ring, resulting in a **phenolic/aromatic ring**. This aromaticity is essential for its binding affinity to estrogen receptors. **Why the Other Options are Incorrect:** * **Testosterone (B):** An androgen (C19 steroid). It contains a keto group at C3 and a double bond between C4 and C5 in the A-ring, but it is **not aromatic**. * **Aldosterone (C) & Cortisol (D):** These are corticosteroids (C21 steroids). Both possess a $\Delta$4-3-keto configuration in the A-ring (a double bond at C4 and a ketone at C3). They lack the planar, resonance-stabilized structure of an aromatic ring. **High-Yield Clinical Pearls for NEET-PG:** * **Aromatase Inhibitors:** Drugs like Anastrozole and Letrozole are used in breast cancer treatment to block the conversion of androgens to estrogens. * **Source of Estrogen:** In postmenopausal women, the primary source of estrogen is the peripheral aromatization of adrenal androstenedione in adipose tissue. * **Solubility:** The aromatic A-ring makes estrogens slightly more acidic than other steroids. * **Precursor:** Testosterone is the immediate precursor to Estradiol, while Androstenedione is the precursor to Estrone.

Q: Which of the following statements regarding the beta-oxidation of palmitic acid is FALSE?

Seven molecules of acetyl-CoA are generated.. ### Explanation **Underlying Concept:** Palmitic acid is a saturated fatty acid containing **16 carbon atoms**. The process of beta-oxidation involves the sequential removal of 2-carbon units in the form of Acetyl-CoA. For a saturated fatty acid with $n$ carbons, the number of Acetyl-CoA molecules produced is $n/2$, and the number of cycles required is $(n/2) - 1$. **Why Option C is FALSE (The Correct Answer):** Since Palmitic acid has 16 carbons, it produces **8 molecules of Acetyl-CoA** ($16 \div 2 = 8$), not seven. The final (7th) cycle of beta-oxidation cleaves a 4-carbon fatty acyl-CoA into two separate 2-carbon Acetyl-CoA molecules. **Analysis of Other Options:** * **Option A:** Correct. To break down a 16-carbon chain into 8 fragments, the enzyme complex must perform the cycle **7 times**. * **Option B:** Correct. Each cycle produces 1 $FADH_2$ (1.5 ATP) and 1 $NADH$ (2.5 ATP). Total from 7 cycles = 28 ATP. The 8 Acetyl-CoA enter the TCA cycle (10 ATP each) = 80 ATP. Gross total = 108 ATP. After subtracting **2 ATP** used for initial activation (Palmitate to Palmitoyl-CoA), the **net yield is 106 ATP**. * **Option D:** Correct. Beta-oxidation occurs in the **mitochondrial matrix**. Long-chain fatty acids require the **Carnitine Shuttle** to cross the inner mitochondrial membrane. **High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme:** Carnitine Palmitoyltransferase-I (CPT-I), which is inhibited by Malonyl-CoA. * **Sudden Infant Death Syndrome (SIDS):** Often associated with **MCAD deficiency** (Medium-chain acyl-CoA dehydrogenase deficiency), the most common inborn error of beta-oxidation. * **Jamaican Vomiting Sickness:** Caused by Hypoglycin A (in unripe Ackee fruit), which inhibits acyl-CoA dehydrogenase, halting beta-oxidation and leading to profound hypoglycemia.

Q: Which of the following is an abnormal lipoprotein?

Lp (a). **Explanation:** The correct answer is **Lp (a)**. While VLDL, LDL, and Chylomicrons are physiological lipoproteins essential for lipid transport, **Lipoprotein (a)** is considered an "abnormal" or "variant" lipoprotein because it is not part of the standard metabolic pathway and is a significant independent risk factor for cardiovascular disease. **Why Lp (a) is the correct answer:** Lp (a) consists of an **LDL-like particle** (containing Apo B-100) covalently linked to a unique glycoprotein called **Apolipoprotein (a)** via a disulfide bridge. It is structurally homologous to **plasminogen** but lacks fibrinolytic activity. Consequently, it competes with plasminogen for binding sites, inhibiting clot lysis and promoting **thrombogenesis**. Its presence in high levels is genetically determined and pathological. **Why other options are incorrect:** * **VLDL (Very Low-Density Lipoprotein):** A normal physiological lipoprotein synthesized by the liver to transport endogenous triglycerides to peripheral tissues. * **Chylomicron:** A normal lipoprotein synthesized by the intestinal mucosa to transport dietary (exogenous) lipids. * **LDL (Low-Density Lipoprotein):** The primary carrier of cholesterol to peripheral tissues; while high levels are "bad," the particle itself is a normal product of VLDL metabolism. **High-Yield Clinical Pearls for NEET-PG:** * **Lp (a) and MI:** It is a potent risk factor for premature coronary artery disease and stroke. * **Niacin:** One of the few drugs that can significantly lower Lp (a) levels (Statins have little to no effect). * **Lipoprotein X:** Another abnormal lipoprotein found specifically in **obstructive jaundice** and LCAT deficiency. * **Broad Beta Disease:** Characterized by the presence of **IDL (Beta-VLDL)**, an abnormal intermediate.

Q: What is the net ATP yield from the complete oxidation of palmitic acid?

106. **Explanation:** The complete oxidation of **Palmitic acid (a 16-carbon saturated fatty acid)** occurs via the Beta-oxidation pathway in the mitochondria. To calculate the net ATP yield, we follow these steps: 1. **Beta-Oxidation Cycles:** A 16-carbon chain undergoes **7 cycles** of beta-oxidation. * Each cycle produces 1 FADH₂ and 1 NADH. * Total: 7 FADH₂ and 7 NADH. 2. **Acetyl CoA Production:** The process yields **8 Acetyl CoA** molecules (16/2). 3. **ATP Calculation (Modern Yield):** * 7 FADH₂ × 1.5 ATP = 10.5 ATP * 7 NADH × 2.5 ATP = 17.5 ATP * 8 Acetyl CoA (via TCA cycle) × 10 ATP = 80 ATP * **Gross Total = 108 ATP** 4. **Activation Cost:** 2 high-energy phosphate bonds are consumed to convert Palmitate to Palmitoyl-CoA (ATP → AMP). * **Net Yield = 108 - 2 = 106 ATP.** **Analysis of Options:** * **Option A (106):** Correct. This reflects the modern P/O ratios (NADH=2.5, FADH₂=1.5). * **Option D (129):** This was the "old" calculation (NADH=3, FADH₂=2). While still found in older textbooks, 106 is the current standard for NEET-PG. * **Options B & C (26 & 16):** These are distractors. 16 is the carbon count; 26 is unrelated to palmitate yield. **Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme:** Carnitine Palmitoyltransferase-I (CPT-I), inhibited by Malonyl-CoA. * **Location:** Beta-oxidation occurs in the mitochondrial matrix; fatty acid synthesis occurs in the cytosol. * **Sudden Infant Death Syndrome (SIDS):** Often associated with **MCAD deficiency** (Medium-chain acyl-CoA dehydrogenase), impairing beta-oxidation.

Q: The reducing equivalents for fatty acid synthesis are derived from which metabolic pathway?

Pentose phosphate pathway. ### Explanation **Correct Answer: D. Pentose Phosphate Pathway (PPP)** Fatty acid synthesis (lipogenesis) is a reductive process that occurs in the cytosol. It requires **NADPH** as the essential reducing equivalent to reduce the keto groups during the elongation of the fatty acid chain. The primary source of this NADPH (approx. 60%) is the **Pentose Phosphate Pathway** (also known as the Hexose Monophosphate Shunt), specifically through the oxidative reactions catalyzed by **Glucose-6-Phosphate Dehydrogenase (G6PD)** and 6-Phosphogluconate Dehydrogenase. Another significant source is the **Malic Enzyme**, which converts malate to pyruvate in the cytosol. **Why other options are incorrect:** * **A. Glycolysis:** This pathway produces **NADH**, not NADPH. NADH is primarily used for ATP production via the electron transport chain, whereas NADPH is used for reductive biosynthesis. * **B. Kreb’s Cycle:** This mitochondrial pathway generates reducing equivalents in the form of **NADH and FADH₂**, which are utilized for oxidative phosphorylation. * **C. Urea Cycle:** This is a metabolic pathway for nitrogen disposal. It does not generate reducing equivalents; in fact, it consumes ATP. **High-Yield Facts for NEET-PG:** * **Rate-limiting enzyme of Fatty Acid Synthesis:** Acetyl-CoA Carboxylase (requires Biotin). * **Tissues with active PPP:** Tissues active in lipid synthesis (Liver, Adipose tissue, Lactating mammary gland, Adrenal cortex) have high PPP activity to supply NADPH. * **Other uses of NADPH:** Steroid synthesis, maintenance of reduced glutathione in RBCs (preventing hemolysis), and the Respiratory Burst in phagocytes (NADPH Oxidase). * **Key Source Mnemonic:** "Fatty acid synthesis needs **NADPH** from the **HMP** shunt and **Malic** enzyme."

Q: Which of the following hormones has a ketogenic effect on the liver?

Glucagon. **Explanation:** **Glucagon** is the primary hormone responsible for stimulating ketogenesis in the liver. During fasting or starvation, the insulin-to-glucagon ratio decreases. Glucagon acts on the liver to decrease levels of **Malonyl-CoA** (by inhibiting Acetyl-CoA Carboxylase). Since Malonyl-CoA is a potent inhibitor of **Carnitine Palmitoyltransferase-I (CPT-I)**, its decrease allows fatty acids to enter the mitochondria via the carnitine shuttle. Once inside, these fatty acids undergo $\beta$-oxidation to produce Acetyl-CoA, which is then diverted into the synthesis of ketone bodies (Acetoacetate and $\beta$-hydroxybutyrate). **Analysis of Incorrect Options:** * **Insulin:** This is the most potent **anti-ketogenic** hormone. It stimulates lipogenesis, increases Malonyl-CoA levels (inhibiting CPT-I), and promotes the peripheral utilization of glucose, thereby suppressing ketone body formation. * **Growth Hormone (GH):** While GH is lipolytic (breaks down fats in adipose tissue), its primary role in the liver is promoting gluconeogenesis and IGF-1 production. It is considered "diabetogenic" but is not the primary driver of hepatic ketogenesis compared to glucagon. * **Androgens:** These are anabolic steroids that influence protein synthesis and secondary sexual characteristics; they have no significant direct regulatory effect on the ketogenic pathway. **High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme of ketogenesis:** HMG-CoA Synthase (mitochondrial). * **Ketone bodies:** Acetoacetate, $\beta$-hydroxybutyrate, and Acetone (a non-metabolizable byproduct). * **Organ utilization:** The liver **produces** ketone bodies but **cannot use** them because it lacks the enzyme **Thiophorase** (Succinyl-CoA:3-ketoacid CoA transferase). * **Diabetic Ketoacidosis (DKA):** Occurs due to absolute insulin deficiency and a relative glucagon excess, leading to unrestrained ketogenesis.

Question 1

Low-density lipoproteins (LDL) represents a final stage in the catabolism of VLDL. Which of the following receptors are present in the liver for uptake of LDL?

Accepted Answer

Apolipoprotein E and Apolipoprotein B100

Answer

Apolipoprotein E

Answer

Apolipoprotein A and Apolipoprotein E

Answer

Apolipoprotein B100

Question 2

The reaction Acetoacetyl CoA + succinate → succinyl CoA + acetoacetate occurs in all of the following tissues except?

Accepted Answer

Liver

Answer

Brain

Answer

Striated muscle

Answer

Cardiac muscle

Question 3

Which of the following is NOT a phospholipid?

Accepted Answer

Cerebroside

Answer

Sphingomyelin

Answer

Cephalin

Answer

Cardiolipin

Question 4

What is the function of LCAT?

Accepted Answer

Converts cholesterol to cholesterol ester

Answer

Helps in cholesterol synthesis

Answer

Helps in the formation of chylomicrons

Answer

All of the above

Question 5

Which of the following contains an aromatic ring?

Accepted Answer

Estradiol

Answer

Testosterone

Answer

Aldosterone

Answer

Cortisol

Question 6

Which of the following statements regarding the beta-oxidation of palmitic acid is FALSE?

Accepted Answer

Seven molecules of acetyl-CoA are generated.

Answer

Seven cycles of beta-oxidation take place.

Answer

A net of 106 ATP molecules are generated.

Answer

Beta-oxidation takes place inside the mitochondria.

Question 7

Which of the following is an abnormal lipoprotein?

Accepted Answer

Lp (a)

Answer

VLDL

Answer

Chylomicron

Answer

LDL

Question 8

What is the net ATP yield from the complete oxidation of palmitic acid?

Accepted Answer

106

Answer

26

Answer

16

Answer

129

Question 9

The reducing equivalents for fatty acid synthesis are derived from which metabolic pathway?

Accepted Answer

Pentose phosphate pathway

Answer

Glycolysis

Answer

Kreb's cycle

Answer

Urea cycle

Question 10

Which of the following hormones has a ketogenic effect on the liver?

Accepted Answer

Glucagon

Answer

Insulin

Answer

Growth Hormone (GH)

Answer

Androgen

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?